Documentation scienceplus.abes.fr version Bêta

À propos de : ▼Natalizumab for multiple sclerosis?        

AttributsValeurs
type
Is Part Of
Subject
Title
  • ▼Natalizumab for multiple sclerosis?
has manifestation of work
Abstract
  • Around 2.5 million people worldwide have multiple sclerosis, of whom about 85,000 are in the UK.1 ▼Natalizumab (pronounced na-ta-liz-you-mab; Tysabri - Biogen Idec), the first in a new class known as selective adhesion-molecule inhibitors, is licensed in the UK as monotherapy for “highly active” relapsing/remitting multiple sclerosis.2 Here we review natalizumab and assess its place for patients with multiple sclerosis.
article type
publisher identifier
  • dt0869
is part of this journal
PubMed ID
  • 18784381



Alternative Linked Data Documents: ODE     Content Formats:       RDF       ODATA       Microdata